News
2024.04.08
"Synthesis for preclinical testing of candidate materials is in progress"
Dx&Vx is focusing its efforts on developing injectable obesity treatment into an oral medication.
Dx&Vx announced on the 8th that it is currently synthesizing candidate materials for preclinical testing of the next-generation oral glucagon-like peptide-1 (GLP-1) obesity treatment.
The GLP-1 receptor agonist market is witnessing significant popularity for injectable GLP-1 obesity treatments due to their potent weight loss effects. However, there is a high incidence of side effects such as pain, nausea, and diarrhea.
Dx&Vx explains that its orally administered formulation under development is more convenient to take than existing injections and carries a lower risk of side effects. Additionally, while maintaining the same mechanism of action as existing injectable GLP-1 obesity treatments—which suppress appetite and increase satiety to induce weight loss—it is expected to have fewer side effects, such as reduced muscle mass and metabolic rate, and fewer gastrointestinal side effects.
As it is developed based on synthetic drugs rather than conventional peptide-based drugs, it is planned to be released at a lower price than injectables.
The GLP-1 market is forecasted to form a massive market of over 100 trillion won by 2030, and with the recent surge in popularity of injectable GLP-1 anti-obesity treatments such as Zepbound and Wegovy, there is a growing interest in the development of oral formulations.
A representative from DxVx stated, "Currently, our sales department distributes and sells obesity treatment drugs to hospitals nationwide, and we have also developed and sell our own brand of diet probiotics series based on microbiome. Therefore, we have established a sales network in the medical channel for obesity and metabolic disease markets." They added, "Ultimately, we will grow into a leading company with a total solution for obesity prevention, diagnosis, treatment, and management."
Source：Bizwatch